Ceftolozane-tazobactam: when, how and why using it?

Citació

  • López Montesinos I, Montero M, Sorlí L, Horcajada JP. Ceftolozane-tazobactam: when, how and why using it? Rev Esp Quimioter. 2021 Sep; 34 Suppl 1(Suppl1):35-7. DOI: 10.37201/req/s01.10.2021

Enllaç permanent

Descripció

  • Resum

    Ceftolozane-tazobactam is currently the most active antipseudomonal agent, including multidrug-resistant extensively drug-resistant strains. Tazobactam provides additional activity against many extended-spectrum beta-lactamases Enterobacterales. Ceftolozane-tazobactam is formally approved for complicated urinary tract infection, complicated intra-abdominal infection, and hospital-acquired and ventilator-associated bacterial pneumonia. The clinical and microbiological success is over 70-80% in many series. However, resistant mutants to ceftolozane-tazobactam have been already described. Combination therapies with colistin or meropenem could be among the strategies to avoid the resistance emergence.
  • Mostra el registre complet